FOSUN PHARMA
复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
4 November 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Pan Donghui and Mr. Chen Yuqing; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

The drug registration applications of Levofloxacin Injection (the "**New Drug 1**") of Yaopharma Co., Ltd.* (重慶藥友製藥有限責任公司) and Cytarabine Injection (the "**New Drug 2**") of Jisimei (Wuhan) Pharmaceutical Co., Ltd* (吉斯美（武漢）製藥有限公司), both being subsidiaries of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**"), were accepted by the National Medical Products Administration respectively.

II. General information and research progress of the New Drug

New Drug 1 and New Drug 2 are all chemical drugs independently developed by the Group (i.e., the Company and its subsidiaries/units, the same below).

New drug 1 is intended for the following mild, moderate and severe infections caused by susceptible bacteria: (1) hospital-acquired pneumonia; (2) community-acquired pneumonia; (3) acute bacterial sinusitis; (4) acute bacterial exacerbation of chronic bronchitis; (5) complex skin and skin structure infections; (6) non-complicated skin and soft tissue infections; (7) chronic bacterial prostatitis; (8) complicated urinary tract infections; (9) acute pyelonephritis; (10) uncomplicated urinary tract infections; and (11) inhalation anthrax (after-exposure).

New Drug 2 is intended to be used (1) in combination with other cytostatic agents for the treatment of acute myelogenous leukemia in adults and children to induce and maintain remission; (2) in the treatment of acute lymphoblastic leukemia, lymphoproliferative crisis and erythrocytosis in chronic myelogenous leukemia; (3) in combination with other cytotoxic drugs for pediatric non-Hodgkin's lymphoma, alone or in combination with other cytostatic agents; (4) for high-dose treatment of acute leukemia; and (5) for intrathecal prophylaxis and treatment of meningoencephalitis with hydrocortisone sodium succinate and methotrexate alone or in combination.

As of September 2024, the Group has invested approximately RMB 1.33 million and RMB 2.57 million (unaudited) in total in the research and development of New Drug 1 and New Drug 2 at current stage, respectively.

According to the latest data of IQVIA CHPA[1], in 2023，the sales of Levofloxacin Injection approved for marketing in China (excluding Hong Kong, Macao, and Taiwan regions) were approximately RMB 2.47 billion, and the sales of Cytarabine Injection were approximately RMB 0.265 billion.

III. Risk Warning

New Drug 1 and New Drug 2 are subject to, among others, obtainment of drug registration approval before commercial production. These acceptance of the drug registration application will not have a material impact on the results of the Group at this stage.

Due to the characteristics of the pharmaceutical products industry, the specific sales performance of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

[1] Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data cover the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.

Board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

4 November 2024

* *For identification purposes only*